Does takeda get deliresp?

[Anonymous]

Now that nycomed has been acquired by takeda, does forest now lose deliresp marketing rights? If this is true it is the final nail in the forest coffin!

 

[Anonymous]

Not 100% sure but I would think that Forest would still have marketing rights in the US and Takeda would take everywhere else in the world. But you are right, if we lose another med we are screwed cause Savella sure isn't gonna save us.

 

[Anonymous]

Now that nycomed has been acquired by takeda, does forest now lose deliresp marketing rights? If this is true it is the final nail in the forest coffin!

Forest has the marketing rights to Daliresp, which is what is is called in the US. Daxas is the same drug, but what it is called in the EU and other markets. When Takeda purchased Nycomed, they got the marketing rights to Daxas, NOT Daliresp.

“Nycomed enables Takeda to maximize the value of our portfolio and gives us an immediate strong presence in the high- growth emerging markets while doubling Takeda’s European sales,” Yasuchika Hasegawa, the company’s president and chief executive officer, said in the statement.

The following is taken directly from a press release on the Forest site:


In August 2009 Forest Laboratories and Nycomed entered into a definitive collaboration and distribution agreement pursuant to which Forest acquired an exclusive license for Daliresp in the United States.

This is from another article:

On April 26, 2010, Nycomed and Merck & Co., Inc. (based in Whitehouse Station, New Jersey and known as MSD outside the USA and Canada) announced that they had entered into an agreement to co-promote Daxas in France, Germany, Italy, Spain, Portugal, and Canada. Nycomed will manufacture and distribute the finished product in all countries covered by the co-promotion agreement. In addition, the two companies have signed an exclusive distribution agreement for the commercialization of Daxas in the United Kingdom. Nycomed will supply finished product and has retained a co-promotion option.

Nycomed submitted a New Drug Application (NDA) to the US Food & Drug Administration (FDA) in July 2009 and has signed a collaboration and distribution agreement for Daxas in the US with Forest Laboratories, Inc. (NYSE: FRX) in August 2009.



So, no I don't think this affects the US marketing rights that Forest has for Daliresp.